{"id":6732,"date":"2026-02-20T17:40:37","date_gmt":"2026-02-20T16:40:37","guid":{"rendered":"https:\/\/hemerapharma.com\/?p=6732"},"modified":"2026-02-26T17:54:38","modified_gmt":"2026-02-26T16:54:38","slug":"macrofagi-riprogrammati-remast-al-simposio-usa","status":"publish","type":"post","link":"https:\/\/hemerapharma.com\/en\/macrofagi-riprogrammati-remast-al-simposio-usa\/","title":{"rendered":"Reprogrammed Macrophage Research REMaST\u00ae presented at International Symposium in Houston"},"content":{"rendered":"<div class=\"ewa-rteLine\">\n<div class=\"ewa-rteLine\"><\/div>\n<div class=\"ewa-rteLine\">At the <a href=\"https:\/\/www.mdanderson.org\/research\/departments-labs-institutes\/programs-centers\/cancer-neuroscience-program\/events.html\" target=\"_blank\" rel=\"noopener\">2026 International Cancer Neuroscience Symposium in Houston (USA)<\/a> the <strong>prestigious scientific forum organized<\/strong> by <a href=\"https:\/\/www.mdanderson.org\/\" target=\"_blank\" rel=\"noopener\">MD Anderson Cancer Center<\/a> and <a href=\"https:\/\/advanced.onlinelibrary.wiley.com\/?msclkid=46f6361d46691f8ec1065fbd336f76c1&amp;utm_campaign=R3MR425-Campaign_Sciad_R3MR425_Pmax_Advanced_106106&amp;utm_content=PMAX&amp;utm_medium=cpc&amp;utm_source=bing&amp;utm_term=advanced.onlinelibrary.wiley.com\" target=\"_blank\" rel=\"noopener\">Advanced Portfolio<\/a>, Professor <a href=\"https:\/\/hemerapharma.com\/en\/team\/francesco-bifari\/\">Francesco Bifari<\/a>, co-founder and Director of Therapy Development at Hemera, was invited to present in the <strong>&#8220;Inflamed Scientists \u2013 Elevator Pitch&#8221;<\/strong> session dedicated to <em><strong>Innate Immunity.<\/strong><\/em><\/div>\n<div class=\"ewa-rteLine\">The invitation recognized his research on the <strong>regenerative potential of reprogrammed macrophages, the scientific foundation underlying Hemera&#8217;s REMaST\u00ae cell therapy platform for the treatment of traumatic spinal cord injury (SCI).<\/strong><\/div>\n<div class=\"ewa-rteLine\">The inclusion in a symposium primarily focused on oncology highlights the <strong>growing international interest in innovative macrophage-based cell therapy approaches with cross-therapeutic applications<\/strong> from regenerative medicine to oncology. The recognition of this research in such a high-profile multidisciplinary setting reinforces the <strong>scientific robustness on which Hemera is building its industrial and strategic development toward a Phase 1 first-in-human clinical trial.<\/strong><\/div>\n<div class=\"ewa-rteLine\">Participation in a global forum of this level expands the international visibility of the REMaST technology and opens new avenues for dialogue with the global scientific and biotech ecosystem, <strong>consolidating Hemera&#8217;s positioning as an innovative player in the field of Advanced Therapy Medicinal Products (ATMP).<\/strong><\/div>\n<div class=\"ewa-rteLine\">Learn more about REMaST therapy <a href=\"https:\/\/hemerapharma.com\/en\/remast%ef%b8%8f\/\">here<\/a><\/div>\n<div class=\"ewa-rteLine\">Read our <a href=\"https:\/\/www.cell.com\/immunity\/fulltext\/S1074-7613(25)00572-2\" target=\"_blank\" rel=\"noopener\">preclinical results published in Immunity\u00a0<\/a><\/div>\n<\/div>\n<div class=\"ewa-rteLine\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>At the 2026 International Cancer Neuroscience Symposium in Houston (USA) the prestigious scientific forum organized by MD Anderson Cancer Center and Advanced Portfolio, Professor Francesco Bifari, co-founder and Director of Therapy Development at Hemera, was invited to present in the &#8220;Inflamed Scientists \u2013 Elevator Pitch&#8221; session dedicated to Innate Immunity. The invitation recognized his research [&hellip;]<\/p>\n","protected":false},"author":10,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[33,31],"tags":[],"class_list":["post-6732","post","type-post","status-publish","format-standard","hentry","category-events","category-news-en"],"acf":[],"_links":{"self":[{"href":"https:\/\/hemerapharma.com\/en\/wp-json\/wp\/v2\/posts\/6732","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hemerapharma.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/hemerapharma.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/hemerapharma.com\/en\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/hemerapharma.com\/en\/wp-json\/wp\/v2\/comments?post=6732"}],"version-history":[{"count":4,"href":"https:\/\/hemerapharma.com\/en\/wp-json\/wp\/v2\/posts\/6732\/revisions"}],"predecessor-version":[{"id":6739,"href":"https:\/\/hemerapharma.com\/en\/wp-json\/wp\/v2\/posts\/6732\/revisions\/6739"}],"wp:attachment":[{"href":"https:\/\/hemerapharma.com\/en\/wp-json\/wp\/v2\/media?parent=6732"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/hemerapharma.com\/en\/wp-json\/wp\/v2\/categories?post=6732"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/hemerapharma.com\/en\/wp-json\/wp\/v2\/tags?post=6732"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}